Stay updated on AstraZeneca PLC ADR Press Releases

Sign up to get notified when there's something new on the AstraZeneca PLC ADR Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the AstraZeneca PLC ADR Press Releases page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page now includes information about Datroway's approval in the US for a specific cancer treatment and highlights Alexion's data presentation at EAN 2025 regarding rare neurological diseases. Notably, previous mentions of significant trial results for Airsupra and AstraZeneca's research showcase have been removed.
    Difference
    76%
    Check dated 2025-06-27T00:22:58.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    AstraZeneca has announced a strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research. The previous mention of Trixeo Aerosphere's approval in the UK has been removed.
    Difference
    8%
    Check dated 2025-06-19T19:04:45.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The page now includes information about the approval of fixed-duration Calquence-based regimens for chronic lymphocytic leukaemia in the EU, while the previous mention of the Imfinzi regimen's trial results for bladder cancer has been removed.
    Difference
    9%
    Check dated 2025-06-12T15:09:21.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The page has been updated with new clinical trial results indicating significant improvements in treatment outcomes for various cancers, while previous trial results have been removed.
    Difference
    85%
    Check dated 2025-06-05T07:48:17.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The page now highlights that Imfinzi has been recommended for approval in the EU as the first and only perioperative immunotherapy for muscle-invasive bladder cancer, while the previous recommendation for Calquence-based regimens for chronic lymphocytic leukaemia has been removed.
    Difference
    9%
    Check dated 2025-05-29T05:35:58.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The webpage has added significant updates regarding AstraZeneca's advancements in breast cancer care and asthma treatment, as well as the completion of the EsoBiotec acquisition. However, it has removed specific updates on other clinical trials and results.
    Difference
    81%
    Check dated 2025-05-22T01:43:51.000Z thumbnail image

Stay in the know with updates to AstraZeneca PLC ADR Press Releases

Enter your email address, and we'll notify you when there's something new on the AstraZeneca PLC ADR Press Releases page.